Abivax to Present Three Obefazimod Abstracts for Ulcerative Colitis at UEG Week 2024

Abivax Announces Presentation of Obefazimod Data at UEG Week 2024 in Vienna

PARIS, France, September 26, 2024 – Abivax SA, a clinical-stage biotechnology company dedicated to the development of therapies that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases, disclosed that it will present three scientific abstracts on its leading drug candidate, obefazimod, at the United European Gastroenterology (UEG) Week from October 12-15, 2024, in Vienna, Austria.

Chief Medical Officer Fabio Cataldi, MD, highlighted the company's anticipation for the event, stating, “We are eager to return to UEGW to share new analysis of our Phase 2b trial data on obefazimod in patients with moderately to severely active ulcerative colitis. The additional evidence from our studies suggests that obefazimod, designed as a once-daily oral therapy, has the potential to significantly advance the treatment paradigm for people living with ulcerative colitis.”

The presentations will include an oral presentation and two moderated poster presentations, underscoring the various facets of obefazimod's efficacy and safety. The oral presentation, to be delivered by Professor Bruce E. Sands, MD, will focus on the efficacy and safety data at weeks 48 and 96 from an open-label maintenance study among clinical non-responders at week 8 of the Phase 2b induction trial. This session is part of the “IBD New Horizons in Medical Treatment - Part 2” and will take place on Tuesday, October 15, 2024, from 11:30 AM to 12:30 PM CEST.

Additionally, two moderated poster presentations are scheduled. The first, presented by Professor Séverine Vermeire, MD, PhD, will discuss the corticosteroid-free efficacy and safety of UC patients receiving obefazimod in a 96-week maintenance study. This presentation, titled “Small Molecules in the Treatment of IBD,” will occur on Tuesday, October 15, 2024, from 14:30 PM to 15:30 PM CEST.

The second poster presentation, delivered by Professor Britta Siegmund, MD, PhD, will examine the impact of obefazimod induction therapy on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis, presenting week 8 results from the Phase 2b induction trial. This session is also part of “Small Molecules in the Treatment of IBD” and is scheduled for Tuesday, October 15, 2024, from 14:30 PM to 15:30 PM CEST.

Obefazimod, Abivax’s lead investigational drug candidate, is an orally administered small molecule that has shown potential in enhancing the expression of a single microRNA, miR-124. Positive data from Phase 2 clinical trials in patients with ulcerative colitis (UC) have catalyzed the initiation of a pivotal global Phase 3 clinical trial program, known as the ABTECT Program, with the first patients enrolled in the United States in October 2022. A Phase 2b clinical trial in Crohn’s disease is anticipated to commence in the third quarter of 2024, alongside ongoing exploration of potential combination therapy opportunities in UC.

Abivax is committed to harnessing the body's natural regulatory mechanisms to manage chronic inflammatory diseases. The company's lead drug candidate, obefazimod, is currently undergoing Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company operates both in France and the United States and continues to advance its clinical programs to provide innovative treatment options for patients.